iNtRODUCtiON
Many patients with breast cancer present with advanced disease at the time of presentation. Increased breast health awareness has led to earlier stage distribution among breast cancer patients; however locally advanced tumors remain a major source of morbidity and mortality specially in the developing and underdeveloped countries. 1, 2 Patients with locally advanced breast cancer have a poor prognosis due to difficulty in achieving local control and eventual development of distant metastases when treated by single modality. Multimodality strategies represent a major advance in manage ment of these difficult cancers. The current stan dard of care is neoadjuvant chemotherapy to improve operability, followed by surgery and radiation therapy. Primary response to induction therapy is an excellent surrogate marker of success in eradi cating micrometastases, as patients experiencing a complete pathologic response have a statistically significant survival advantage 2 , hence an accu rate assessment of chemotherapeutic response is crucial. Clinical examination of the breast has to date been the most widely used approach for response assessment, having the advantages of being simple, quick, easy and non-invasive. However, this method varies among observers, is influenced by many factors such as skin thickness, edema and obesity 3, 4 and could result in overestimation of tumour size 5 . In today's era of evidence-based medicine, the efficacy of clinical examination alone is increasingly being questioned. Clinical evaluation alone for assessing tumor response to neoad juvant chemotherapy in breast carcinoma (WHO and UICC criteria) 6 shows limitations in practica bility and reliability. Warr et al. estimated the error in categorization of response by comparing measurements of several physicians on real or simulated malignant lesions 7 . They found false categorization of partial response (based on a comparison of two measurements of the same lesion) to the tune of 1.3% and 12.6% for large and small simulated nodules, respectively.
In view of the importance of assessment of chemotherapeutic response in breast carcinoma, confident noninvasive assessment of response remains one of the "holy grails" of medicine today. The various non-invasive methods being advocated are mammography, B mode sonography, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PeT) and Color Doppler sonography. Fiorentino et al. in 
patiENts aND MEthODs
This prospective study was undertaken in 25 patients with locally advanced breast carcinoma, showing presence of hypervascular signals in breast masses on pre-chemotherapy Color Doppler ultrasonography, and who received neoadjuvant chemotherapy. The patients were in the age range of 30 to 65 years with a mean age of 44.52 ± 10.24 years and all were histologically proven cases of invasive ductal carcinoma. Of the twenty-five patients included in the study, five patients had breast lump as the only presenting symptom, while 20 patients had other associated symptoms along with the breast lump including mass in the axilla, ulceration/fungation, pain and nipple discharge. Clinically, the tumor diameter ranged from 4.9-10.3cms with a mean of 7.48 ± 1.72cms. The duration of symptoms ranged from 2-24 months and the mean duration was 9.5 months. All patients received 3-4 cycles of neoadjuvant chemotherapy FAC (a combination 5-Fluorouracil, Doxorubicin and Cyclophosphamide) at three weekly intervals prior to mastectomy. Patients were clinically evaluated prior to chemotherapy and finally prior to surgery. The breast lump was measured along two diameters perpendicular to each other using Vernier calipers 10 and the mean diameter was calculated. Clinical tumor volume (Vc) was calculated using the formula for the volume of a sphere,Vc=π/6 X d3 where d = mean diameter in centimeters. A single experienced radiologist performed sonographic and Color Doppler examination. In order to avoid bias, the sonologist was blinded to the patient's clinical profile, treatment history, response status and the pre-chemotherapy findings when assessing the pre-surgery findings. The mass was scanned by using a LA39, 11 MHz probe (LOGIQ 4000L, Ge Medical systems). The scan was done in multiple planes to include the whole breast and axilla. Normal and 13-mode images were taken to define the tumor margins. The probe was held orthogonal to the skin and moved over the tumor till maximum diameter was demonstrated. Two measurements were made perpendicular to each other and the thickness of the lesion was recorded using the equipment's electronic calipers. sonographic tumor volume (Vs) was calculated using the formula for the volume of an ellipsoid, Vs=π/6X d1xd2xD where d1, d2= diameter of tumor in centimeters D = depth of tumor in centimeters.
The breast lump seen on normal and B mode was then evaluated using Color Doppler sonography. standardized machine settings were used to optimize sensitivity to low velocity and low volume blood flow (wall filter-low frequency; dynamic range-60 dB; persistence-short; colour threshold-50). Data acquisition was limited to a region of interest ("Color box") containing the tumor. The number of flow signals, maximum flow velocity (Vmax), resistivity index (RI) and pulsatility index (PI) of intratumoral vessels were recorded. The number of flow signals was assessed by manual counting of pixels inside the tumor mass. Peritumoral flow was not taken into account for assessment. evaluation was done prior to chemotherapy and prior to surgery. Clinical response was calculated as a percentage of change in the tumor volume (Vc). The percentage of change in sonographic tumor volume (Vs), Vmax, RI and PI was recorded. A change in the number of flow signals was also noted. An experienced pathologist who was blinded to the clinical response status of the patient evaluated the mastectomy specimen and the extent of post chemotherapy changes was assessed. Response assessed on the basis of various criteria was graded as shown in table 1.
statistical analysis
The grades of response were compared and analyzed with the help of Pearson correlation coefficient and Kappa statistics. Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) of various parameters for assessing complete pathological response were calculated. 14 lymphocytic infiltrates and tumor necrosis. (Table 3) . Correlation of various parameters assessed in the study with the histological response is summarized in 
REsUlts
Twenty-four (96%) of 25 patients showed a clinical regression in tumor volume following chemotherapy. Five cases (20%) had complete disappearance of the lesion. sonographically the tumor diameter ranged from 1.08-5.6 cms with a mean of 3.62 ± 1.33 cms. Twenty-three (92%) of 25 patients showed a sonographic regression in tumor volume following chemotherapy. The mean RI of tumoral blood flow was 0.789 ± 0.259 at the time of presentation. eleven (44%) of 25 patients showed regression of RI following chemotherapy while two patients showed an increase in Rl. The mean PI of tumoral blood vessels at the time of presentation was 1.450 ± 0.579. Nine (36%) of 25 patients showed regression in PI following chemotherapy while four (16%) patients showed an increase in PI. Mean Vmax for tumoral blood flow at the time of presentation was 0.375 ± 0.305 m/sec. Thirteen (52%) of 25 patients showed regression in Vmax following chemotherapy. Twelve patients (48%) showed complete disappearance of flow signals following chemotherapy and hence RI, PI and Vmax could not be recorded post-chemotherapy. The response was assessed on the basis of Doppler parameters as shown in table 2. Figure 1 and 2 show the changes in intratumoral flow signals following chemotherapy.
Nine patients (36%) showed histological complete response to chemotherapy referred to as total annihilation while 8 patients (32%) each showed minimal and moderate changes in the form of stromal fibrosis, 16 . In the present study also, 40% of patients with complete clinical response had residual tumor on histology, while 55% of patients with complete pathological response had palpable tumor on clinical examination. such observations are attributed to the presence of residual fibrosis and indistinct tumor margins that is sequelae of tumor response to chemotherapy. The present study thus emphasizes the inadequacy of clinical criteria alone for response assessment. Based on these observations the use of various imaging modalities for this purpose has been explored, the common ones being mammography and B-mode sonography. Cocconi et al. showed that clinical assessment of response should be supported by mammography 17 . However, these methods are purely anatomical and have limitations as they are unable to assess the extent of viable tumor cells. Keeping in mind this limitation and the strong relationship between the tumor growth and blood flow, a method capable of evaluating the angiogenic activity of the tumor should provide more functional evidence of viable tumor cells. Dynamic MR Mammography has been reported to be of value for the estimation of residual disease after induction chemotherapy 18 . However, this modality lacks applicability, particularly in the developing countries, due to limited availability and lesser cost effectiveness.
In the search for a cost effective, easily accessible functional method for response assessment, the role of Color Doppler sonography has been evaluated. Lagalla et al. evaluated 
DisCUssiON
The impact of breast cancer on women's health continues to assume greater importance in developing countries. The often advanced stage of the disease at the time of presentation necessitates the use of neoadjuvant chemotherapy as the primary treatment modality. The role of neoadjuvant chemotherapy is important for downstaging the tumor and making definitive surgery feasible. This therapeutic approach however requires an accurate assessment of response to chemotherapy. The response assessment helps in distinguishing responders from non-responders, that reflects the survival rate.
Response assessment may also help to identify a subgroup of women in whom intensification of treatment might be expected to treat micrometastases more effectively. The extent of downstaging of the tumor can be estimated on the basis of chemotherapeutic response. This in turn helps in identifying a subset of patients in whom conservative, less mutilating surgery can be performed without increasing the rate of local recurrence 15 . Finally, response assessment can be used as a surrogate parameter of treatment efficacy and may allow early termination of inefficacious regimens. and histological response. The study confirmed a greater correlation between Doppler and histological response as compared to clinical response and histological response.
Among the various Doppler parameters the number of residual flow signals was found to be the only independent parameter. All the others were found to be dependent on the presence or absence of residual flow, as these could not be assessed in the cases in which there was complete disappearance of flow signals following chemotherapy. Doppler response was also found to have a higher sensitivity of 88.88% for predicting complete pathological response, compared to 44.44% for clinical response. We can conclude that Color Doppler thus seems to be an additional and independent functional method in the assessment of tumor response to neoadjuvant chemotherapy in locally advanced breast carcinoma.
